BACKGROUND: Prostein is a recently described molecule expressed at the mRNA level in a prostate-specific manner. A murine monoclonal antibody was developed, characterized, and used to evaluate the expression of prostein protein in prostatic, other normal tissue and tumor samples. METHODS: The murine anti-prostein monoclonal antibody 10E3-G4-D3 was generated using recombinant prostein. ELISA, FACS, and Western analyzes were used to characterize 10E3-G4-D3. Immunohistochemistry was used to characterize the expression of prostein in tissues. RESULTS: 10E3-G4-D3 specifically recognizes a linear intracellular epitope of prostein. IHC analysis demonstrates that prostein is expressed in the vast majority of normal and malignant prostatic tissues, regardless of grade and metastatic status. No protein expression is detected in a panel of approximately 4,700 normal and malignant tissue samples representing the great majority of essential tissues and tumors. CONCLUSIONS: Prostein is exquisitely specific for prostate tissues, indicating a potential clinical utility of 10E3-G4-D3 as a diagnostic biomarker, and support the use of prostein as a novel target for development of prostein-specific antibody and T-cell based therapeutic strategies for prostate cancer. Copyright 2004 Wiley-Liss, Inc.
BACKGROUND:Prostein is a recently described molecule expressed at the mRNA level in a prostate-specific manner. A murine monoclonal antibody was developed, characterized, and used to evaluate the expression of prostein protein in prostatic, other normal tissue and tumor samples. METHODS: The murine anti-prostein monoclonal antibody 10E3-G4-D3 was generated using recombinant prostein. ELISA, FACS, and Western analyzes were used to characterize 10E3-G4-D3. Immunohistochemistry was used to characterize the expression of prostein in tissues. RESULTS: 10E3-G4-D3 specifically recognizes a linear intracellular epitope of prostein. IHC analysis demonstrates that prostein is expressed in the vast majority of normal and malignant prostatic tissues, regardless of grade and metastatic status. No protein expression is detected in a panel of approximately 4,700 normal and malignant tissue samples representing the great majority of essential tissues and tumors. CONCLUSIONS:Prostein is exquisitely specific for prostate tissues, indicating a potential clinical utility of 10E3-G4-D3 as a diagnostic biomarker, and support the use of prostein as a novel target for development of prostein-specific antibody and T-cell based therapeutic strategies for prostate cancer. Copyright 2004 Wiley-Liss, Inc.
Authors: Bora Gurel; Tehmina Z Ali; Elizabeth A Montgomery; Shahnaz Begum; Jessica Hicks; Michael Goggins; Charles G Eberhart; Douglas P Clark; Charles J Bieberich; Jonathan I Epstein; Angelo M De Marzo Journal: Am J Surg Pathol Date: 2010-08 Impact factor: 6.394
Authors: Alessandro Conti; Matteo Santoni; Luciano Burattini; Marina Scarpelli; Roberta Mazzucchelli; Andrea B Galosi; Liang Cheng; Antonio Lopez-Beltran; Alberto Briganti; Francesco Montorsi; Rodolfo Montironi Journal: World J Urol Date: 2015-12-22 Impact factor: 4.226
Authors: Emma E van der Toom; Haley D Axelrod; Jean J de la Rosette; Theo M de Reijke; Kenneth J Pienta; Kenneth C Valkenburg Journal: Nat Rev Urol Date: 2019-01 Impact factor: 14.432
Authors: Angela Queisser; Susanne A Hagedorn; Martin Braun; Wenzel Vogel; Stefan Duensing; Sven Perner Journal: Mod Pathol Date: 2014-06-13 Impact factor: 7.842
Authors: Hanka Jähnisch; Susanne Füssel; Andrea Kiessling; Rebekka Wehner; Stefan Zastrow; Michael Bachmann; Ernst Peter Rieber; Manfred P Wirth; Marc Schmitz Journal: Clin Dev Immunol Date: 2010-11-04
Authors: A Zaccagnino; C Pilarsky; D Tawfik; S Sebens; A Trauzold; I Novak; A Schwab; H Kalthoff Journal: Eur Biophys J Date: 2016-09-21 Impact factor: 1.733